York, PA – BioTechnique®, a contract development and research organization (CDMO), announced the acquisition of a large manufacturing/ fill- finish facility located in York, Pennsylvania. This facility replaces BioTechnique’s® former Madison, Wisconsin site divested in 2018.
BioTechnique® will offer formulation and aseptic fill/finish services with lyophilization capacity for both clinical and commercial clients. The 163,885 square foot manufacturing facility is situated on 38 acres of land. The facility was constructed in 2010 and has 120,000 square feet of combined warehouse and manufacturing space, of which 42,000 square feet are ISO 7 and ISO 8 cleanrooms. Justin Cantor, Chief Strategy Officer of PSC Biotech® and BioTechnique®, says “Our new facility has a significant size advantage relative to many other CDMOs. We believe having the extra production space will allow our clinical customers to confidently proceed to commercial manufacturing in the same facility with the same staff to ensure minimal disruptions when scaling to commercial volumes. Additionally, this is not only an opportunity to bring more jobs to the area, but it also allows us to further expand our manufacturing capabilities and meet the growing contract manufacturing needs necessitated by COVID-19”.
The York County Economic Alliance, the Governor’s Action Team and the Commonwealth of Pennsylvania provided financing support. PSC Biotech Corporation and Samuel Li and Susan Yang of East West Bank completed the transaction.
The new BioTechnique® facility features:
- 163,885 square feet of innovative technology and automated state-of-the-art manufacturing systems to ensure drug product quality.
- Future physical plant growth and expansion opportunities on the site.
- Capability to produce sterile injectable drugs from clinical to commercial batch sizes.
- Career opportunities for at least 100 new production, research & development, engineering, quality, and sales staff.
BioTechnique® is actively seeking partners and innovative life sciences companies in search of a world class manufacturing platform.
About BioTechnique®: BioTechnique® is a sterile injectable manufacturing company dedicated to providing cytotoxic and high potency sterile injectable fill-finish services. From investigational/clinical to final marketed product, BioTechnique® can provide fill finish services to batch sizes both big and small. Learn more at www.BioTechnique.com.